Tvardi Therapeutics Stock Plummets Following IPF Trial Setback

Tvardi Therapeutics has experienced a significant decline in its stock price after disappointing results from a trial for idiopathic pulmonary fibrosis (IPF). BTIG has lowered its price target to $15, reflecting investor concerns about the company's future in treating this condition. The setback raises questions about the viability of its treatments, impacting both investor confidence and patient prospects.